To degrade or inhibit, that’s the question
Continuing our coverage of the targeted protein degradation niche, we take an in-depth look at the updated clinical data on bavdegalutamide and put the initial findings in some context.
While it’s always fun to write about the early science and preclinical data, the proof of the pudding ultimately comes from the clinical trials and whether a novel agent can impact people with cancer in positive ways such that they feel better and live longer.
In this latest example, we look at what’s happening in advanced prostate cancer, an area where we are seeing a new renaissance with a variety of therapies being tested…
BSB subscribers can read our latest commentary – you can either log-in or click to access.
This content is restricted to subscribers
